SRPT vs. JAZZ, IONS, MRTX, RARE, PTCT, TAK, ALNY, TEVA, GMAB, and RPRX
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceutical preparations" industry.
Sarepta Therapeutics (NASDAQ:SRPT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, community ranking, profitability, valuation and dividends.
Sarepta Therapeutics presently has a consensus target price of $164.47, suggesting a potential upside of 49.28%. Jazz Pharmaceuticals has a consensus target price of $192.75, suggesting a potential upside of 83.33%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Sarepta Therapeutics.
Sarepta Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
Jazz Pharmaceuticals has higher revenue and earnings than Sarepta Therapeutics. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Sarepta Therapeutics' net margin of 1.20%. Jazz Pharmaceuticals' return on equity of 27.86% beat Sarepta Therapeutics' return on equity.
Sarepta Therapeutics received 330 more outperform votes than Jazz Pharmaceuticals when rated by MarketBeat users. However, 80.54% of users gave Jazz Pharmaceuticals an outperform vote while only 75.38% of users gave Sarepta Therapeutics an outperform vote.
In the previous week, Sarepta Therapeutics had 4 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 15 mentions for Sarepta Therapeutics and 11 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.15 beat Sarepta Therapeutics' score of 0.74 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Jazz Pharmaceuticals beats Sarepta Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
